newsfilter
← Latest News
GlobeNewswire·

AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update

AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update Phase 2 interim results suggest treatment with active immunotherapy ACI-7104 may slow the progression of Parkinson's diseaseNLRP3